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Abstract
Background: Swine origin influenza A/H1N1 infection (H1N1) emerged in early 2009 and rapidly spread to
humans. For most infected individuals, symptoms were mild and self-limited; however, a small number developed
a more severe clinical syndrome characterized by profound respiratory failure with hospital mortality ranging from
10 to 30%. While supportive care and neuraminidase inhibitors are the main treatment for influenza, data from
observational and interventional studies suggest that the course of influenza can be favorably influenced by agents
not classically considered as influenza treatments. Multiple observational studies have suggested that HMGCoA
reductase inhibitors (statins) can exert a class effect in attenuating inflammation. The Collaborative H1N1 Adjuvant
Treatment (CHAT) Pilot Trial sought to investigate the feasibility of conducting a trial during a global pandemic in
critically ill patients with H1N1 with the goal of informing the design of a larger trial powered to determine impact
of statins on important outcomes.
Methods/Design: A multi-national, pilot randomized controlled trial (RCT) of once daily enteral rosuvastatin versus
matched placebo administered for 14 days for the treatment of critically ill patients with suspected, probable or
confirmed H1N1 infection. We propose to randomize 80 critically ill adults with a moderate to high index of
suspicion for H1N1 infection who require mechanical ventilation and have received antiviral therapy for ≤ 72 hours.
Site investigators, research coordinators and clinical pharmacists will be blinded to treatment assignment. Only
research pharmacy staff will be aware of treatment assignment. We propose several approaches to informed
consent including a priori consent from the substitute decision maker (SDM), waived and deferred consent. The
primary outcome of the CHAT trial is the proportion of eligible patients enrolled in the study. Secondary outcomes
will evaluate adherence to medication administration regimens, the proportion of primary and secondary
endpoints collected, the number of patients receiving open-label statins, consent withdrawals and the effect of
approved consent models on recruitment rates.
Discussion: Several aspects of study design including the need to include central randomization, preserve
allocation concealment, ensure study blinding compare to a matched placebo and the use novel consent models
pose challenges to investigators conducting pandemic research. Moreover, study implementation requires that trial
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the pandemic.
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Background
Influenza and Swine Origin Influenza A/H1N1 Infection
(H1N1)
On June 11, 2009, the World Health Organization
(WHO) declared that infection with the Swine Origin
Influenza A/H1N1 virus had reached pandemic propor-
tions [1]. Cases were recorded in more than 180 coun-
tries and outbreaks that strained national resource
capacities were documented in Canada, Australia, Chile,
Argentina, and elsewhere.
Throughout history, pandemic influenza has posed a
recurrent threat to human populations. Seasonal influ-
enza is responsible for more than 50,000 deaths per year
in the United States [2]. The capacity of the influenza
virus to mutate and spread from animals to humans has
resulted in intermittent pandemics. The 1918 pandemic
was the largest in recent history and caused between 40
and 50 million deaths worldwide [3]. Smaller pandemics
in 1957 and 1968 were associated with mortality spikes
but their effects were mild at the population level [4].
Experts believe further pandemics will certainly occur,
but are uncertain about when. Several years ago, the
avian H5N1 influenza virus threatened to be the vector
of the next pandemic. While highly virulent when trans-
mitted from infected chickens to humans, the absence
of human-to-human transmission resulted in a small
number of cases worldwide [5].
In early 2009, a novel strain of influenza, swine origin
influenza A/H1N1 infection (H1N1) emerged in swine
and rapidly spread to humans [6]. Originating in
Mexico, the strain proved highly infectious and was spread
by person-to-person contact with a predilection for
younger hosts. While early epidemiologic data suggested
that although H1N1 was highly infectious, it was less viru-
lent [7,8] than anticipated with a case fatality rate of
approximately 0.5% of infected individuals. For the major-
ity of infected individuals, symptoms were mild and self-
limited; however, a small percentage of infected individuals
developed profound respiratory failure requiring extraor-
dinary means of oxygenation support including high fre-
quency oscillation (HFO) ventilation and extracorporeal
membrane oxygenation (ECMO) [9]. Caring for the most
severely ill patients during a pandemic results in an
increased need for intensive care unit (ICU) resources and
strains available personnel and equipment. There is little
excess capacity to care for critically ill patients in most
developed countries, and minimal capacity in developing
countries.
Rationale for Study Intervention
Supportive care and antiviral agents, especially neuramini-
dase inhibitors (such as oseltamivir and zanamivir), are the
mainstay of treatment for influenza. While efficacious in
reducing viral load and abating symptoms in ambulatory
patients, their effects on outcomes in critically ill patients
have not been established. Their utility in treating severe
pandemic H1N1 influenza may be compromised by wide-
spread use and emergence of viral resistance [10,11], lim-
ited supplies, policies regarding treatment strategies, and
cost and availability, especially in developing countries [12].
Human and animal data suggest that the course of influ-
enza may be favorably influenced by certain agents not
classically considered as treatments for influenza [13-16]
that are comparatively inexpensive and readily available.
Such agents may provide independent benefit in treating
viral infection and are attractive as adjuvant treatments.
Statin Therapy for Influenza
Statins lower plasma lipid levels by inhibiting HMG CoA
reductase, the enzyme responsible for converting HMG
CoA to mevalonate, a rate-limiting step in cholesterol
biosynthesis. Multiple observational studies have sug-
gested that statins may be of benefit in patients with a
v a r i e t yo fs e v e r ei n f e c t i o n s[ 1 7 - 2 2 ]b ye x e r t i n ga ne f f e c t
in attenuating inflammation [23,24]. The mechanism of
this activity is uncertain but may involve their ability to
restrict cholesterol availability in cell membranes of the
innate immune system. Cholesterol is a key component
of lipid rafts, membrane-associated microdomains that
support cell signaling in response to exogenous inflam-
matory stimuli. Raft disruption may attenuate the cellular
response to inflammatory stimuli [25,26].
Experimental studies show that pre-treatment with
statins attenuates the severity of acute lung injury (ALI)
following intestinal ischemia-reperfusion [27] and the
inflammatory response to intravenous lipopolysaccharide
challenge in human volunteers [28]. The combination of
a statin and caffeine inhibits viral replication and attenu-
ates lung injury in murine influenza models [29]. Popu-
lation-based studies suggest that statins are associated
with reduced inflammatory morbidity in critically ill
patients receiving them [20] and reduced mortality in
patients with influenza and chronic obstructive pulmon-
ary disease (COPD) patients [30]. Reviewing 3,921 hos-
pitalized patients with laboratory confirmed influenza, of
whom 1,019 were receiving a statin at the time of
admission, Vandermeer and colleagues found that statin
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death (adjusted OR = 0.34, 95% CI: 0.16-0.70) in a mul-
tivariable logistic regression model [31]. The benefits of
statins appear to be best established in patients receiving
them prior to the onset of infection. Cohort studies
report conflicting results on the ability of statins to
attenuate organ dysfunction with Schmidt and collea-
gues finding that statins reduce mortality in critically ill
patients with multiple organ dysfunction syndrome [32]
and Kor et al reporting that statin use was not beneficial
in resolving organ dysfunction [33].
Rosuvastatin: Risks and Benefits
Statins are widely used and well-tolerated medications.
Rosuvastatin differs from other HMG CoA reductase inhi-
bitors in that only up to 10% of the parent compound is
metabolized by cytochrome P450 2C9 and 2C19 and not
by P450 3A4 [34]. As a result, it exhibits fewer drug-drug
interactions, and serum concentrations are not affected by
CYP2D6 gene polymorphism. Adverse events seen with
rosuvastatin are generally mild and may include muscle
symptoms, however, myopathy and rhabdomyolysis occur
infrequently in patients taking 40 mg/day or less. As with
other HMG-CoA reductase inhibitors, a dose-related
increase in liver transaminases and creatinine kinase (CK)
has been observed in small numbers of patients taking
rosuvastatin. The overall occurrence of clinically signifi-
cant transaminase increases is low (< 1%) and similar
across rosuvastatin doses ranging from 5 mg/day to 40
mg/day [35]. Patients with severe liver disease may have
increased exposure to rosuvastatin [35].
Study Objective
The International Forum of Acute Care Trialists
(InFACT) is an informal alliance of investigator-led clin-
ical trials networks whose remit is to improve the care
of critically ill patients through the promotion of scienti-
fically rigorous clinical research. Based on our prelimin-
ary understanding of H1N1 influenza, members of the
Canadian Critical Care Trials Group (CCCTG), working
in collaboration with members of InFACT, designed the
Collaborative H1N1 Adjuvant Treatment (CHAT) Pilot
Trial to investigate the feasibility of conducting an inter-
national therapeutic trial during a global pandemic and
the potential for adjuvant rosuvastatin, in addition to
standard treatment, to influence clinical outcomes in
influenza A (H1N1) associated critical illness.
Methods
Study Design
A multi-national feasibility RCT involving adult ICUs
in Canada, Saudi Arabia, Mexico, Argentina Australia/
New Zealand. An overview of the study design is pro-
vided in Figure 1 (see Figure 1).
Primary Objective
[1] The ability to recruit the desired patient population
under pandemic conditions (i.e., the proportion of eligi-
ble patients enrolled in the CHAT Pilot Trial).
Secondary Objectives
[2] Adherence to the medication administration regimen
as outlined in the study protocol.
[3] The ability to collect the required primary and sec-
ondary endpoints for the planned full CHAT trial.
[4] The number of patients who receive open-label
statins.
[5] The number of consent withdrawals.
[6] The impact of approved consent models on
recruitment rates.
Patient Screening
A dedicated research coordinator will screen patients for
eligibility on a daily basis in the ICUs at participating
sites. If the study inclusion criteria are fulfilled and no
exclusion criteria are present, the research coordinator
will identify the patient as a potential study participant.
The attending physician or intensivist will confirm elig-
ibility for participation in the CHAT Pilot RCT.
Inclusion Criteria
Criteria to identify potential candidates for study inclu-
sion will include:
1) Critically ill adult patients ≥ 16 years of age
admitted to an adult ICU for any reason with sus-
pected, probable or confirmed novel swine origin
influenza A/H1N1 infection (see Additional File 1).
2) Requiring mechanical ventilation (invasive or non-
invasive)
3) Receiving antiviral therapy (any medication at any
dose and for any intended duration) for ≤ 72 hours
4) Attending physician or intensivist must have a
‘moderate’ to ‘high’ index of suspicion for H1N1.
Exclusion Criteria
1) Age < 16 years
2) Do not resuscitate or re-intubate order documen-
ted on chart or anticipated withdrawal of life support
Placebo Oral Rosuvastatin   
Oral Rosuvastatin  
Mechanical Ventilated 
Critically Ill Adults with 
Probable, Suspected or 
Confirmed H1N1 
R
Figure 1 Study Overview.
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4) Unable to receive or unlikely to absorb enteral
study drug (e.g., incomplete or complete bowel
obstruction, intestinal ischemia, infarction, short
bowel syndrome)
5) Rosuvastatin specific exclusions:
a. Already receiving a statin
b. Allergy or intolerance to statins.
c. Receiving niacin, fenofibrate, cyclosporine,
gemfibrozil, any protease inhibitor (including but
not limited to lopinavir and ritonavir) or planned
use of oral contraceptives or estrogen therapy
during the ICU stay.
d. CK exceeds 5,000 U/L or ALT exceeds 8
times the upper limit of normal (ULN).
6) Severe chronic liver disease (Child-Pugh Score 11-
15) (see Additional File 2)
7) Previous enrolment in this trial
8) Pregnancy or breast feeding
9) At the time of enrolment, receipt of > 72 hours of
antiviral therapy.
10) Known or suspected clinically significant myosi-
tis or myopathy.
Eligible, Non-Randomized Patients
We will record reasons why eligible patients are not
randomized into the CHAT Pilot Trial under the follow-
ing categories:
a) Substitute Decision Maker (SDM) consent refusal
b) Physician refusal of consent
c) SDM not available to provide consent and waived/
deferred consent not permitted
d) SDM does not exist and waived/deferred consent
not permitted
e) Coordinator workload
f) Coordinator not available during eligible time-
window
g) Enrolment in a competing trial
h) Other (specification required)
To enhance trial feasibility and given the need to con-
duct a pragmatic trial, co-enrolment in other prospective
observational studies or RCTs (not investigating similar
or alternative H1N1 treatments) in operation in the ICU
setting will be permitted and recorded in sites where per-
mitted by the local Research Ethics Boards (REBs) [36].
Study Randomization
To preserve allocation concealment, participants will be
randomized centrally. Randomization lists will be dis-
tributed by the study methods centre to the research
pharmacies of participating centres. Stratified variable
block randomization, based on centre alone, will be per-
formed to take into consideration differences in patient
characteristics at participating ICUs. Day one will be
considered the day of study treatment initiation, which
may or may not be the same day of randomization.
Consent
A waiver of consent is the preferred option for partici-
pant enrollment given the context of a global pandemic.
We have constructed a consent algorithm to direct the
consent process at sites where the local REB has not
approved a waiver of consent (see Additional File 3). In
this trial, we will request that patients be enrolled in the
study, and consent be deferred to SDMs or to the
patient (whomever is able to provide consent first),
when it is not possible to obtain consent within
24 hours. Consent may be obtained in person or by tele-
phone as per local practices. In the event that patients
die before providing consent, we request permission
from REBs to include data collected during study
participation.
Study Treatment Overview
Using randomization lists provided by the study methods
centre, research pharmacists will assign critically ill adults
to once daily enteral administration of rosuvastatin or
matched placebo for 14 days. Only the research pharmacy
staff will be aware of the assigned treatment arm. The site
investigators, research coordinator, clinical pharmacist
involved in the care of the patient and all other study per-
sonnel will remain blinded to treatment assignment. An
oral placebo for nasogastric administration, identical in
appearance (colour and consistency matched) to crushed
rosuvastatin, will be prepared by Pharmacy 1 (Toronto,
Canada) and supplied to the study sites. All other aspects
of patient management will be left to clinician discretion
as per pragmatic trial design. The Applied Health
Research Centre of the Keenan Research Centre and Li Ka
Shing Knowledge Institute (St Michael’s Hospital, Tor-
onto, Ontario) will be the Study Methods Centre.
Study Drug Administration
Delivery Route
Study drug will be administered once daily through an
enteral feeding tube or orally if the patient is able to
safely take oral medications. The type and placement of
the enteral feeding tube (nasogastric, nasoenteric, percu-
taneous endoscopic gastrostomy, orogastric, oroenteric,
etc.) will be at the discretion of the attending clinical
team. The ability to safely take oral medications will be
determined by the patient’s primary care team.
Initial Dose
The first study drug dose (rosuvastatin or placebo) will
be administered within 4 hours of randomization as a
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(Chinese, Korean, Japanese, Phillipino, Vietnamese, or
Asian-Indian) descent, age <18 years or has serum crea-
tinine greater than or equal to 248 umol/L (2.8 mg/dL)
(see requirements for dose adjustments below).
Subsequent Doses
Thereafter doses of 20 mg will be administered at 22:00
hrs daily (+/- 4 hours) starting on the next calendar day
(study day 2) as a maintenance dose. If the patient is of
Asian descent, is <18 years, or serum creatinine is
greater than or equal to 248 umol/L (2.8 mg/dL) dose
adjustments will be required according to the dose
adjustment algorithm (see requirements for dose adjust-
ments below). Dose adjustment is only necessary for
patients with renal impairment and not receiving dialy-
sis. Once dialysis is started and serum creatinine
remains elevated, dose adjustment is not required.
Missed Doses
If for any reason a maintenance dose is not adminis-
tered at the intended time, it may be administered sub-
sequently but not more than 12 hours after the
intended time of administration. If greater than
12 hours has elapsed since the last scheduled dose, the
patient will receive another loading dose, and then
maintenance dosing will resume on the next calendar
day as outlined above. A missed dose, for reasons other
than outlined under medication discontinuation will be
considered a protocol violation.
Dose Adjustments
The loading (40 mg) and daily maintenance (20 mg)
doses will be reduced by 50% for patients:
a) who have at least one parent of Asian descent
(loading 20 mg and daily 10 mg),
b) whose age < 18 years (loading 20 mg and daily
10 mg),
c) whose serum creatinine concentration is greater
than or equal to 248 umol/L (2.8 mg/dL) who are
not on renal replacement therapy (loading 20 mg
and daily 10 mg), and by 75% for patients:
d) who have at least one parent of Asian descent
and/or age < 18 years and serum creatinine is
greater than or equal to 248 umol/L (2.8 mg/dL)
(loading 10 mg and daily 5 mg).
Concomitant Medication Administration
Intermittent oral antacids should be administered no
closer than 6 hours before or after administering rosu-
vastatin to avoid influencing study drug absorption [37]
Duration of Treatment
Given the substantial potential for false negative influ-
enza results, we will continue adjuvant treatment
administration, regardless of H1N1 testing results
(positive or negative), for 14 days or until a criterion
for cessation is met. If patients are liberated from
mechanical ventilation (invasive or non-invasive) and
discharged from the ICU between days 1 and 9 they
will be advanced to day 10 of study drug administra-
tion. In the event that patients remain in the ICU for
observation (e.g., possible reintubation or initiation of
non-invasive ventilation) then study drug administra-
tion will NOT be advanced to day 10 until they are
discharged.
Completion of Study Drug Administration
Study drug administration will be stopped when one of
the following conditions is met, whichever comes first:
1. 14 days after randomization
2. Hospital discharge (including transfer to an alter-
nate care facility)
3. Death
4. CK noted to exceed 5,000 U/L (in the absence of an
alternative diagnosis) or patient is determined to have
clinical myositis or myopathy (at the discretion of the
primary care team, patient may be re-challenged with
study drug if CK or clinical findings no longer meet
this criterion).
5. Alanine aminotransferase (ALT) exceeds 8 times
the ULN (in the absence of an alternative diagnosis)
6. Co-administration of any of the following: niacin,
fenofibrate, cyclosporine, gemfibrozil, lopinavir, rito-
navir, oral contraceptives or estrogen
7. Attending physician or intensivist or SDM request
to stop treatment.
We will request for data collection to continue in
patients withdrawn from therapy prematurely. Clinicians
will be encouraged to continue study medication despite
negative H1N1 testing due to the potential for false
negative results and the potential role for an anti-
inflammatory agent (rosuvastatin) in severe lung disease.
Decisions regarding continuation or discontinuation of
antiviral treatment will be left to the discretion of the
attending physician or intensivist.
Study Co-interventions
It will not be feasible to protocolize ventilator and gen-
eral clinical management under pandemic conditions.
Adjunctive non-antibiotic, non-interventional manage-
ment of sepsis, acute respiratory distress syndrome, and
glycemic control will be at the discretion of the patient’s
primary clinicians. Key aspects of clinical management
(such as choice of antiviral, dose of administration,
duration of treatment, ventilator strategy, treatment
with inhaled nitric oxide, HFO, prone positioning,
ECMO, additional antiviral/anti-inflammatory treat-
ments and treated episodes of infection) will be docu-
mented either as part of the Influenza A H1N1 (Swine
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separate data forms for centres not participating in the
registry. Antibiotic therapy may be prescribed for sus-
pected or confirmed concomitant bacterial infection at
the discretion of the attending physician.
H1N1 Testing
Local testing procedures may be used to facilitate diag-
nosis of H1N1. Where no local testing procedures exist,
we recommend using the following initial and repeat
testing procedures. For all new admissions to adult
ICUs meeting study inclusion criteria and having no
exclusion criteria with non-confirmed H1N1 (i.e., all
suspected or probable cases) or where uncertainty exists
regarding prior testing, we request the following
sequence of laboratory tests:
Initial Diagnostic Testing (assuming diagnosis not
confirmed at ICU admission)
1. Paired deep nasopharyngeal (NP) swab AND either an
endotracheal (ET) aspirate or bronchoalveolar (BAL) (or
sputum if not intubated) for (a) influenza polymerase
chain reaction (PCR) and (b) viral culture; and
2. Endotracheal aspirate (or sputum if not intubated)
for gram stain, culture and sensitivity (C & S)
Repeat Testing (for patients with one positive test)
1. Repeat both tests (PCR and viral culture) from the
site that was positive previously (i.e., ET or BAL or NP
swab). If both ET and NP swab were positive,s e n d
repeat ET aspirate specimen at day 7 and at weekly
intervals thereafter.
2. After the first negative specimen(s) from a pre-
v i o u s l yp o s i t i v es i t e ,s e n dar e p e a ts p e c i m e nf r o mt h e
same site at 48 hours after the first specimen was
collected.
Drug Level Specimen Collection
To verify adequate absorption of rosuvastatin, we will
draw venous blood for peak and trough plasma rosuvas-
tatin concentrations (total of 2 specimens) on day 7 (+/-
1 day). Day 7 will be the preferred day for trough and
peak specimen collection. A trough level specimen will
be drawn prior to day 7 (+/- 1 day) dose. A peak con-
centration specimen will be drawn 3 to 5 hours after the
dose of study drug is administered. A maximum of 80
patients will have blood drawn for drug concentration
analysis; however, only patients randomized to rosuvas-
tatin will have their samples analyzed. Samples will be
labeled and batched at the site, for shipment to St
Michael’s Hospital (Toronto, Canada) for analysis after
the study is unblinded.
Follow-Up
Research staff will assess participants daily for adverse
effects for the duration of treatment. CHAT study
participants will have daily CK and liver function [aspar-
tate aminotransferase (AST) and ALT] levels collected
as part of the study protocol. Study drug will be discon-
tinued if hypersensitivity is suspected (see Criterion 7
Completion of Study Drug Administration).
We will record the number of patients receiving full
treatment and reasons for the inability to complete the
assigned treatment duration (i.e., death, transfer to an
alternate care facility, study withdrawal, etc). The study
Data Safety and Monitoring Board (DSMB) will review
all patients withdrawn from the study, safety data, and
deaths.
All patients will be followed until death or hospital
discharge. We will record the vital status of all patients
at 90 days and hospital discharge, whichever occurs
first. At day 60 patients remaining on the ventilator
will be deemed ventilator dependent. Randomized
patients will be considered successfully extubated when
they remain off positive pressure ventilation (invasive
or non-invasive ventilation) for 48 consecutive hours.
If patients are re-intubated within 48 hrs following
extubation, they will be followed until they achieve
one of the aforementioned outcomes. Patients dis-
charged from the ICU and requiring readmission and
re-initiation of mechanical ventilation (invasive or non-
invasive) will be treated according to usual practice
and will not be randomized on a second occasion to
this study.
Study Outcomes
Primary Outcome
[1] Proportion of eligible patients enrolled in the CHAT
pilot study.
Secondary Outcomes
[2] Adherence to the medication administration regimen
as outlined in the study protocol.
[3] Proportion of completed primary and secondary
endpoints for the planned full CHAT trial that are
collected.
[4] Number of patients who receive open-label statins.
[5] Number of consent withdrawals.
[6] Recruitment rates by approved consent model.
Sample Size Estimation (CHAT Pilot Trial)
Estimates are not available to allow precise sample size
estimation of the primary outcome for the proposed
CHAT pilot RCT. We propose to undertake a pilot
study in a convenience sample of 80 patients with sus-
pected, probable or confirmed H1N1 infection to assess
trial feasibility.
Data Collection
We will collect CHAT specific data starting at ICU
admission using paper-based versions of the electronic
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H1N1 (Swine Flu) ICU (Registry) Study [7]. The forms
will document baseline characteristics, enrolment into
concurrent influenza research studies, co-morbidities,
illness severity (see Additional File 4), vaccination sta-
tus, co-interventions, feasibility outcomes and clinical
outcomes for the planned definitive trial (primary: the
proportion of patients successfully weaned from
mechanical ventilation in less than 10 days; secondary:
impact of rosuvastatin on ICU, 60 and 90 day, and
hospital mortality and on ICU free days at day 60). In
addition to the data forms developed for the Influenza
A H1N1 (Swine Flu) ICU study, we developed 13 addi-
tional forms including an (i) eligibility and randomiza-
tion form, (ii) severity of illness form, (iii) consent
form, (iv) drug administration form, (v) H1N1 diagnos-
tic test results form, (vi) laboratory data form,
(vii) drug level (serum) specimen collection form,
(viii) 60 day and 90 day outcomes form, (ix) comments
and end of study investigator sign off, (x) protocol viola-
tion form: biochemistry, (xi) protocol violation form:
medication administration/discontinuation, (xii) adverse
event form, (xiii) serious adverse event form in rando-
mized patients. For centres not participating in the reg-
istry, we drafted 10 additional forms to capture
necessary demographic, treatment and outcomes infor-
mation. In addition, we drafted a form to capture demo-
graphic data and outcomes on eligible but not
randomized patients.
Statistical Analysis
Descriptive statistics will be used to summarize the data.
For univariate analyses, we will use the Chi-square test
(alternatively, Fisher’s exact test when the expected cell
size is ≤ 5) and Student’s t-test (alternatively, the Mann-
Whitney U-test, if normality assumptions are not satis-
fied) for binary and continuous outcomes, respectively.
All analyses will be conducted on an intention-to-treat
basis.
F e a s i b i l i t yf o rt h ep i l o ts t u d yw i l lb ea s s e s s e db y
metrics that reflect our capacity to ultimately recruit a
representative sample of 1,050 patients in the planned
full CHAT trial. We will consider the study to be feasi-
ble if we recruit at least 30% (commonly used threshold
in ICU studies) of all eligible patients in participating
ICUs through careful review of site screening logs.
Additionally, we expect that: (i) less than 10% of medi-
cation doses will fail to be administered in the absence
of meeting one of the medication discontinuation cri-
teria; (ii) less than 5% of data forms will be missing
important primary and secondary outcomes data
required for the planned full CHAT trial and (iii) no
more than 10% of enrolled patients will be withdrawn
prematurely due to open label use of statins or
withdrawal of consent. We will describe recruitment
rates based on approved consent models. Since centres
in Australia and New Zealand will be permitted to use
Atorvastatin and matching placebo (instead of Rosuvas-
tatin/matching placebo), we propose to conduct the
planned primary and secondary analyses (i) using the
pooled data (rosuvastatin plus atorvastatin) and (ii)
using rosuvastatin (as the predominantly used statin in
the CHAT Trial) data alone.
A DSMB will oversee the trial and will consist of 3
individuals with expertise in viral infectious diseases,
statistics and clinical critical care of which one will be
international. The DSMB will hold a teleconference
after either 30 patients have evaluable data or approxi-
mately 8 months after study initiation. Should the trial
be completed, feasibility data from the pilot study will
be analyzed by the DSMB at the end of the study. This
information will be conveyed to the Steering Committee.
Together the DSMB and Steering Committee will for-
mulate a decision whether to proceed with the full trial.
Clinical outcomes will remain blinded by study group
assignment with a view to including them in the
planned larger trial.
Adverse Event Reporting
Investigators will evaluate any changes in laboratory
values and physical signs and will determine if the
change is clinically important and different from what is
expected in the course of treatment of critically ill
patients requiring mechanical ventilation for suspected,
probable or confirmed influenza. If clinically important
and unexpected adverse experiences occur, they will be
recorded on an adverse event case report form. We will
characterize adverse events (see Additional File 5) as
expected, serious unexpected and study related or
unanticipated.
Other Considerations
We considered other factors (see Additional File 6)
including patient withdrawals, consent (including tele-
phone consent and waivers of consent) (see Additional
Files 7 and 8), eligible non- randomized patients, equita-
ble selection of subjects, justification for including
vulnerable subjects, women of childbearing age, justifica-
tion for excluding pregnant women, trial oversight and
the trial data safety and monitoring board (see Addi-
tional File 6) in designing the CHAT Trial protocol.
The investigators plan to make changes to the larger
study protocol based on their experience in implement-
ing the pilot trial. Regardless, we will publish the find-
ings of the CHAT Pilot Trial, either alone or pooled
with another trial evaluating the role of statins in a simi-
lar population, if recruitment ensues even if the study
protocol is modified in important ways following
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never comes to fruition. Pilot trial data may also be
combined with data from the larger trial if the latter
trial comes to fruition, study personnel (including the
data analyst) remain blinded to treatment assignment
and no important modifications are made to the study
protocol following the pilot trial.
Discussion
Global concern arose from the threat of the H1N1
influenza pandemic. Despite the potential virulence of
the illness, little is actually known about how severe
disease develops or what treatments may confer benefit
to critically ill patients. Even less is known about how
to conduct clinical research in the setting of an evol-
ving pandemic. Severe H1N1 infection primarily affects
young and often previously healthy individuals. Early
reports supported that aboriginal populations in
Canada and Australia, obese individuals and women,
especially pregnant women, appear to have a predilec-
tion for severe disease. Unlike the pandemic of 1918,
the availability today of antiviral agents, antibiotics for
s e c o n d a r yi n f e c t i o n ,a n dI C Us u p p o r t i v ec a r ei n t e r v e n -
tions holds promise that the majority of patients with
severe illness can be saved. The burden of severe
H1N1 disease falls prominently on the ICU [8,38].
Consequently, the opportunity to learn about treat-
ments for severe H1N1 disease and how to conduct
pandemic critical care research rests within the ICU
community.
Data from observational studies in humans and inter-
ventional studies in animals, suggests that the course of
influenza may be favorably influenced by relatively inex-
pensive and readily available agents, such as rosuvasta-
tin, that are not classically considered to be treatments
for influenza. These agents are attractive as adjuvant
treatments amidst emerging reports of oseltamivir resis-
tance and threatened drug supply shortages. However,
the ability to administer and test the efficacy of an adju-
vant agent as a treatment for severe H1N1 infection
remains to be established.
The CHAT pilot trial is designed to evaluate the feasi-
bility of implementing a randomized controlled trial of
adjuvant rosuvastatin for treating severe H1N1 infection
under a pandemic. We aim to evaluate whether centres
can adhere to the study treatment regimens, collect the
required primary and secondary endpoints for the sub-
sequent planned full CHAT trial, and document patients
who receive open-label statins and consent withdrawals.
We also seek to evaluate the impact of approved con-
sent models on recruitment rates.
Several time-honored aspects of RCT design including
the use of central randomization, preservation of alloca-
tion concealment, multi-level study blinding, and use of
a matching placebo posed challenges to us in designing
a pandemic protocol. We contemplated the necessity of
including each of these study design features. After care-
ful deliberation, we decided to include central randomi-
zation (using lists distributed by the study methods
centre to participating centres), preserve multi-level
blinding (by involving pharmacies at participating cen-
tres) and contract a local pharmaceutical company to
prepare crushed drug and matching placebo (in the
absence of industry supply of study drug and an avail-
able placebo). Recognizing that trial initiation may be
delayed and recruitment curtailed if a priori in-person
SDM consent was required, we considered use of alter-
native consent models. A priori in-person SDM consent
not only hinges on the existence and availability of
SDMs [39], but also the ability of SDMs to access hospi-
tals during a pandemic.
Strengths of the proposed pilot trial design include
the use of central randomization, allocation conceal-
ment, multi level blinding, standard criteria for medica-
tion discontinuation, and 90 day follow up. To ensure
feasibility during a pandemic, we did not protocolize
H1N1 testing, ventilator and sedation management or
the clinical use of antibacterial agents. By merging study
data with an Influenza Registry and capturing data on
unique forms for centres not participating in the regis-
try, we will, however, document key aspects of clinical
management.
The conduct of an RCT during an evolving pandemic
poses unique challenges not encountered during other
forms of clinical research [40]. First, it is necessary to
initiate studies quickly. The normal time interval from
concept to first patient enrolment for a new RCT is
typically of the order of two years or more. Second, the
scope and duration of the pandemic is unknown and
unpredictable. Third, the mitigating effects of large-scale
vaccination programs and changes in H1N1 infectivity
resulting from virus mutation are unknown. Fourth, the
practicalities of conducting clinical research during a
pandemic are unknown. For example, research person-
nel may be seconded to provide clinical care, pharma-
cists may face challenges in dispensing drug and
placebo, REBs may not permit alternative consent mod-
els and it may be difficult to obtain consent from
patients who may lack decision-making capacity and
families, who may be unwell themselves, unable to visit
the hospital or requested to stay away during the pan-
demic. Finally, faced with the clinical imperative of
treating gravely ill and previously well, young patients,
clinicians may opt to use open label treatment rather
than permit enrolment into a blinded RCT. Because we
believe that it is important to develop the capacity to
initiate RCTs under pandemic conditions and to test
study procedures prior to implementing a large scale
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assess the feasibility of our clinical protocol and study
procedures.
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classification of adverse events.
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Additional file 8: Telephone Consent. File containing telephone
consent.
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